Measuring how broadly neutralizing antibodies can target HIV reservoirs
Official title: Quantifying bNAb neutralization of the HIV latent reservoir
Funded at Icahn School of Medicine at Mount Sinai · NIH-11059938 · Data updated 2026-11-12
This study is looking at how well certain antibodies can fight HIV hidden in the body, especially in people who have their virus under control, to find better ways to treat them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $421,500 |
| NIH project number | 5R61AI176585-03 |
| Project ID | NIH-11059938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are HIV-positive individuals who are virologically suppressed and may benefit from antibody-based therapies.
✕Less likely to help
Patients who are not HIV-positive or those who are not virologically suppressed may not receive any benefit from this research.
What this research studies
This research investigates the effectiveness of broadly neutralizing antibodies (bNAbs) in targeting and neutralizing HIV, particularly focusing on the latent reservoirs of the virus in patients. The approach involves developing a new assay that can quantify the sensitivity of these reservoirs to bNAbs, which could help identify the best candidates for treatment. By using advanced flow cytometry techniques, the study aims to improve the understanding of how these antibodies can activate immune responses against HIV-infected cells. Patients with virologically suppressed HIV will be the primary focus, as the research seeks to enhance treatment strategies for them.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV, potentially improving outcomes for patients with the virus.
How similar studies have gone: Other research has shown promise in using broadly neutralizing antibodies for HIV treatment, indicating that this approach has potential for success.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Chen, Benjamin K — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chen, Benjamin K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.